This move is archived. Current quotes and coverage live on the stock page.
Get MSCL alerts:
Satellos Bioscience Inc. is making waves with a notable intraday gain of 1.65%, closing at CA$8.65.
In the latest trading session, Satellos Bioscience Inc. (MSCL.TO) saw its stock price rise by 1.65%, reflecting positive investor sentiment. This uptick comes as the company continues to advance its clinical trials and explore new avenues for growth.
Investor takeaway: Investors may find Satellos Bioscience's focus on innovative treatments for Duchenne muscular dystrophy appealing, especially as the company progresses in its clinical trials.
Advertisement
Satellos Bioscience Inc.
MSCL.TO
MSCL.TO
Satellos Bioscience Inc.
WealthAwesomeMarket cap
$280.06M
52W high
$18.98
52W low
$7.32
1W change
+11.17%
Beta
1.14
Analyst Price Targets
Based on analyst covering MSCL
Wall Street analysts forecast MSCL stock price to rise 26.8% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$17.67
+26.8% Upside
Current Price
C$13.93
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MSCL's historical volatility
30-Day Vol
50.7%
Annualized
90-Day Vol
72.5%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$16.65
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$14.78 | C$12.41 โ C$17.61 |
| 60 trading days | C$15.69 | C$12.25 โ C$20.09 |
| 90 trading days | C$16.65 | C$12.30 โ C$22.54 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Satellos Bioscience Inc. Gains 1.65% in One Day
With a market cap of CA$170.8 million, Satellos's stock performance reflects growing investor interest in its innovative approaches.
Bull case
The recent dosing of the first adult patient in the LT-001 study marks an important step forward for Satellos. This progress could lead to significant breakthroughs in treatment options for Duchenne muscular dystrophy.
Bear case
Despite today's gains, Satellos still faces challenges common in the biotech sector, such as uncertainty around clinical trial outcomes and how the market will respond to its developments.
Recent Developments
Advertisement
Satellos has recently announced the dosing of its first adult patient in the LT-001 study, aimed at evaluating the long-term effects of SAT-3247 for Duchenne muscular dystrophy. This milestone is crucial as it shows the company's commitment to advancing its clinical programs.
Market Performance
The stock's rise to CA$8.65 today reflects a broader interest in biotech stocks, particularly those focusing on rare diseases. With a market cap of CA$170.8 million, investors are closely watching Satellos for potential breakthroughs that could enhance its market position.
Looking Ahead
As Satellos continues its clinical trials, investors should keep an eye on upcoming announcements regarding trial results and further developments in their product pipeline, which could significantly impact stock performance.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
